Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, dose-ranging, efficacy and tolerability study in chronic kidney disease
patients with hyperphosphatemia on hemodialysis. Patient participation in the study is
approximately 10 weeks in duration.